Attovia Therapeutics Files for Nasdaq IPO With Morgan Stanley and Citi

Attovia Therapeutics, Inc. submitted its registration to list on Nasdaq under the proposed ticker ATTO, with Morgan Stanley and Citigroup serving as co-lead underwriters on the offering. The filing, dated July 14, 2026, marks the company's formal entry into the public-market process and signals that management believes conditions are favorable enough to begin the road to a listing.

The move arrives as biotechnology's IPO market has been rebuilding momentum through 2026 after a prolonged downturn. Attovia's decision to tap two major bulge-bracket banks as co-leads suggests the company is targeting institutional investors and aiming for a credible, well-distributed debut. Pricing terms, including deal size, share count, and an expected price range, have not yet been disclosed in the filing.

Investors tracking the offering will want to watch for an amended S-1 that includes a preliminary price range, which typically arrives weeks before the actual pricing date. The SEC filing is the primary source of record for Attovia's financials, risk factors, and use of proceeds as more details become available.